Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | PALB2 R170fs |
| Gene Variant Detail | |
| Relevant Treatment Approaches | PARP Inhibitor (Pan) |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| PALB2 R170fs | bladder urachal adenocarcinoma | predicted - sensitive | PARP Inhibitor (Pan) | Talazoparib | Case Reports/Case Series | Actionable | In a Phase II trial, Talzenna (talazoparib) treatment resulted in a clinical benefit rate (CBR) of 22.8% (18/79, 1 complete and 7 partial responses, 10 with stable disease >/=24 weeks) in patients with advanced solid tumors harboring mutations in DNA damage repair genes, including a partial response lasting 17 weeks in a urachal adenocarcinoma patient harboring PALB2 R170fs14 (PMID: 39085400; NCT02286687). | 39085400 |